Li Wang,Juan Lu,Yi Liu,Yunfei Gao,Man Kong,Jiandong Yang,Bin Kong,Xuebing Li,Xifen Huang,Wenzhong Pei. A retrospective analysis of the safety and efficacy of apatinib in treating advanced metastatic colorectal cancer. Oncol Transl Med, 2017, 3: 210-216. |
A retrospective analysis of the safety and efficacy of apatinib in treating advanced metastatic colorectal cancer |
Received:July 18, 2017 Revised:October 16, 2017 |
View Full Text View/Add Comment Download reader |
KeyWord:colorectal cancer; targeted therapy; apatinib; vascular endothelial growth factor receptor-2 (VEGFR-2); angiogenesis inhibitor |
Author Name | Affiliation | Department | Li Wang | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Juan Lu | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Yi Liu | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Yunfei Gao | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Man Kong | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Jiandong Yang | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Bin Kong | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Xuebing Li | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Xifen Huang | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology | Wenzhong Pei | Department of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China | Department of Oncology |
|
Hits: 8173 |
Download times: 9020 |
Abstract: |
Objective Colorectal cancer (CRC) is a heterogeneous disease in which both epigenetic alterations and
gene mutations transform normal cells into cancer cells. Apart from a variety of standard treatments, there
are few options available to improve a CRC patient’s overall survival (OS) and quality of a life. The objective
of the present retrospective study was to analyze the response and toxicity associated with apatinib in
patients with metastatic CRC (mCRC).
Method Data on the use of apatinib as salvage therapy were collected from patients diagnosed with
mCRC, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3, from the Luhe Hospital. A
total of 17 patients with stage IV unresectable mCRC, who received at least one cycle of apatinib, between
October 2015 and February 2017, were involved in this study. Our primary endpoints were the overall
response rate (ORR) and disease control rate (DCR), and the secondary objectives were progression-free
survival (PFS), OS and safety.
Result Seventeen patients with a median age of 62 years (34–83 years) were enrolled. Twelve
patients were male, and the location of the primary tumor was in the colon and the rectum in 9 and 8
patients, respectively. Liver metastasis was observed in 9 patients and lung metastasis in 5. The ECOG
performance status was 0 to 2 in 13 patients. The ORR at the first evaluation was 17.6 % (3/17). The DCR
was 82.4% (14/17). The median PFS was 3.0 months (95% confidence interval (CI): 1.924–4.076 months)
and the median OS was 5.4 months (95% CI: 3.383–7.417 months). Grade 1–2 adverse events included
hypertension (52.9%), fatigue (64.7%), anorexia (29.4%), hoarseness (23.5%), proteinuria (23.5%), and
development of rashes (17.6%). Grade 3 adverse events included thrombocytopenia (5.9%) and proteinuria
(5.9%). There were no Grade 4 adverse events in our analysis.
Conclusions Apatinib was found to be both safe and effective in the treatment of advanced mCRC, and
its associated toxicities were acceptable and manageable. However, further studies are required to validate
these findings. |
Close |
|
|
|